Recurrent vulvovaginal candidiasis (RVVC), despite its worldwide prevalence, has limited treatment options; and a long‐term prophylactic regimen utilising fluconazole is the dominant choice. Click to show full abstract
Recurrent vulvovaginal candidiasis (RVVC), despite its worldwide prevalence, has limited treatment options; and a long‐term prophylactic regimen utilising fluconazole is the dominant choice.
               
Click one of the above tabs to view related content.